Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2023 1
2024 1
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean del pozo jl (177 results)?
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
Vieira SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, Menozzi E, Mullin S, Yalkic S, Limbachiya N, Koletsi S, Loefflad N, Lopez GJ, Gan-Or Z, Alcalay RN, Sidransky E, Schapira AHV. Vieira SRL, et al. Among authors: del pozo sl. Mov Disord. 2024 Dec;39(12):2144-2154. doi: 10.1002/mds.30006. Epub 2024 Sep 11. Mov Disord. 2024. PMID: 39258449 Free PMC article. Review.
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Jul 1;11(1):193. doi: 10.1038/s41531-025-01041-9. NPJ Parkinsons Dis. 2025. PMID: 40593721 Free PMC article.
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Taylor KI, Lipsmeier F, Scelsi MA, Volkova-Volkmar E, Rukina D, Popp W, Lambrecht S, Anzures-Cabrera J, Summers D, Abt M, Monnet A, Kilchenmann T, Schjodt-Eriksen J, Essioux L, Kustermann T, Zago W, Svoboda H, Nikolcheva T, Postuma RB, Pagano G, Lindemann M; PASADENA Investigators; Prasinezumab Study Group. Taylor KI, et al. NPJ Digit Med. 2025 Jun 16;8(1):365. doi: 10.1038/s41746-025-01572-8. NPJ Digit Med. 2025. PMID: 40523921 Free PMC article.
Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline.
Rodríguez-Antigüedad J, Martínez-Horta S, Puig-Davi A, Horta-Barba A, Pagonabarraga J, de Deus Fonticoba T, Jesús S, Cosgaya M, García Caldentey J, Ávila-Rivera MA, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Gómez Mayordomo V, González Ardura J, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Mendoza Z, Pareés I, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Ruíz Martínez J, Buongiorno MT, Ordás C, Valero C, Puente V, Kurtis M, Blázquez Estrada M, Martínez-Martín P, Mir P, Santos-García D; COPPADIS Study Group; Kulisevsky J. Rodríguez-Antigüedad J, et al. J Neurol. 2025 Mar 5;272(3):246. doi: 10.1007/s00415-024-12808-0. J Neurol. 2025. PMID: 40042541 Free PMC article.
Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials.
Menozzi E, Del Pozo SL, Macnaughtan J, Mezabrovschi R, Koletsi S, Mitrotti P, Gallo L, Calabrese R, Toffoli M, Loefflad N, Valzania F, Cavallieri F, Fioravanti V, Yalkic S, Limbachiya N, Blandini F, Avenali M, Schapira AH. Menozzi E, et al. Among authors: del pozo sl. NPJ Parkinsons Dis. 2025 Oct 1;11(1):281. doi: 10.1038/s41531-025-01063-3. NPJ Parkinsons Dis. 2025. PMID: 41034226 Free PMC article.
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.
Pagano G, Trundell D, Simuni T, Pavese N, Marek K, Postuma RB, Shariati N, Monnet A, Moore E, Davies EW, Svoboda H, Pross N, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. NPJ Parkinsons Dis. 2025 Aug 13;11(1):241. doi: 10.1038/s41531-025-01103-y. NPJ Parkinsons Dis. 2025. PMID: 40804248 Free PMC article. No abstract available.
Cognitive impairment and dementia in young onset Parkinson's disease.
Santos-García D, de Deus Fonticoba T, Cores Bartolomé C, Feal Painceiras MJ, García Díaz I, Íñiguez Alvarado MC, Paz JM, Jesús S, Cosgaya M, García Caldentey J, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Ávila Rivera MA, Gómez Mayordomo V, Nogueira V, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Mendoza Z, Martínez Castrillo JC, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Kulisevsky J, Seijo M, Valero C, Alonso Redondo R, Buongiorno MT, Ordás C, Menéndez-González M, McAfee D, Martinez-Martin P, Mir P; COPPADIS Study Group. Santos-García D, et al. J Neurol. 2023 Dec;270(12):5793-5812. doi: 10.1007/s00415-023-11921-w. Epub 2023 Aug 14. J Neurol. 2023. PMID: 37578489
Correction: Heterogeneity of cognitive progression and clinical predictors in Parkinson's disease-subjective cognitive decline.
Rodríguez-Antigüedad J, Martínez-Horta S, Puig-Davi A, Horta-Barba A, Pagonabarraga J, de Deus Fonticoba T, Jesús S, Cosgaya M, García Caldentey J, Ávila-Rivera MA, Caballol N, Legarda I, Hernández Vara J, Cabo I, López Manzanares L, González Aramburu I, Gómez Mayordomo V, González Ardura J, Dotor García-Soto J, Borrué C, Solano Vila B, Álvarez Sauco M, Vela L, Escalante S, Cubo E, Mendoza Z, Pareés I, Sánchez Alonso P, Alonso Losada MG, López Ariztegui N, Gastón I, Ruíz Martínez J, Buongiorno MT, Ordás C, Valero C, Puente V, Kurtis M, Blázquez Estrada M, Martínez-Martín P, Mir P, Santos-García D; COPPADIS Study Group; Kulisevsky J. Rodríguez-Antigüedad J, et al. J Neurol. 2025 Apr 26;272(5):362. doi: 10.1007/s00415-025-13077-1. J Neurol. 2025. PMID: 40285930 Free PMC article. No abstract available.